Spontaneous and genetically engineered animal models; use in preclinical cancer drug development

Area of Science:

• Oncology
• Comparative Medicine
• Drug Development

Background:

• Traditional preclinical anticancer drug development relies heavily on transplanted cancer models in mice.
• These models often fail to fully recapitulate human cancer complexity and progression.
• There is a need for more relevant preclinical models to improve drug efficacy and translation.

Purpose of the Study:

• To review the utility and integration of spontaneous cancer models in preclinical anticancer drug development.
• To compare genetically engineered mouse models and naturally occurring cancers in pet animals.
• To provide examples and assess the relative strengths and weaknesses of these models.

Main Methods:

• Literature review of spontaneous cancer models in mice and companion animals.
• Analysis of case studies demonstrating successful application in drug development.
• Comparative assessment of model systems based on biological relevance and predictive value.

Main Results:

• Genetically engineered mouse models offer controlled genetic alterations leading to cancer.
• Naturally occurring cancers in pet dogs and cats exhibit remarkable similarities to human cancers.
• Spontaneous models provide a more comprehensive platform for evaluating drug efficacy and toxicity.

Conclusions:

• Spontaneous cancer models, both engineered and naturally occurring, represent valuable alternatives to transplantation models.
• Integrating these models into preclinical research can enhance the development of effective anticancer therapies.
• Further research and validation of spontaneous models are crucial for advancing oncology drug discovery.